CombiMatrix to Launch up to Four More CMDX Tests in '07, Prepares Spin-Out from Acacia | GenomeWeb
CombiMatrix Molecular Diagnostics will launch at least two more diagnostic assays this year in an effort to flood the array-based molecular diagnostics market before better-funded rivals in the space can catch up, according to a company official.
Amit Kumar, CEO of CMDX parent CombiMatrix, told investors during the company’s first-quarter earnings call two weeks ago that the firm plans to introduce a number of tests through its CMDX subsidiary this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.